Logo do repositório
 

Antibiotic treatment schemes for very severe community-acquired pneumonia in children: a randomized clinical study

dc.contributor.authorRibeiro, Cristiane Franco [UNESP]
dc.contributor.authorFerrari, Giesela Fleischer [UNESP]
dc.contributor.authorFioretto, José Roberto [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-20T13:38:01Z
dc.date.available2014-05-20T13:38:01Z
dc.date.issued2011-06-01
dc.description.abstractObjective. To compare clinical response to initial empiric treatment with oxacillin plus ceftriaxone and amoxicillin plus clavulanic acid in hospitalized children diagnosed with very severe community-acquired pneumonia (CAP).Methods. A prospective randomized clinical study was conducted among children 2 months to 5 years old with a diagnosis of very severe CAP in the pediatric ward of São Paulo State University Hospital in Botucatu, São Paulo, Brazil, from April 2007 to May 2008. Patients were randomly divided into two groups by type of treatment: an oxacillin/ceftriaxone group (OCG, n = 48) and an amoxicillin/clavulanic acid group (ACG, n = 56). Analyzed outcomes were: time to clinical improvement (fever and tachypnea), time on oxygen therapy, length of stay in hospital, need to widen antimicrobial spectrum, and complications (including pleural effusion).Results. The two groups did not differ statistically for age, sex, symptom duration before admission, or previous antibiotic treatment. Time to improve tachypnea was less among ACG patients than OCG patients (4.8 +/- 2.2 versus 5.8 +/- 2.4 days respectively; P = 0.028), as was length of hospital stay (11.0 +/- 6.2 versus 14.4 +/- 4.5 days respectively; P = 0.002). There were no statistically significant differences between the two groups for fever improvement time, time on oxygen therapy, need to widen antimicrobial spectrum, or frequency of pleural effusion.Conclusions. Both treatment plans are effective in treating very severe CAP in 2-monthto 5-year-old hospitalized children. The only analyzed outcome that favored amoxicillin/clavulanic acid treatment was time required to improve tachypnea.en
dc.description.affiliationUniv Estadual Paulista, Fac Med Botucatu, Dept Pediat, Botucatu, SP, Brazil
dc.description.affiliationUnespUniv Estadual Paulista, Fac Med Botucatu, Dept Pediat, Botucatu, SP, Brazil
dc.format.extent444-450
dc.identifierhttp://dx.doi.org/10.1590/S1020-49892011000600010
dc.identifier.citationRevista Panamericana de Salud Publica-pan American Journal of Public Health. Washington: Pan Amer Health Organization, v. 29, n. 6, p. 444-450, 2011.
dc.identifier.doi10.1590/S1020-49892011000600010
dc.identifier.issn1020-4989
dc.identifier.lattes9566480326705225
dc.identifier.scieloS1020-49892011000600010
dc.identifier.urihttp://hdl.handle.net/11449/13186
dc.identifier.wosWOS:000293651800010
dc.language.isoeng
dc.publisherPan Amer Health Organization
dc.relation.ispartofRevista Panamericana de Salud Publica - Pan American Journal of Public Health
dc.relation.ispartofjcr0.784
dc.relation.ispartofsjr0,452
dc.rights.accessRightsAcesso aberto
dc.sourceWeb of Science
dc.subjectPneumoniaen
dc.subjectanti-bacterial agentsen
dc.subjectrandomized clinical trialen
dc.subjectchild, preschoolen
dc.subjectinfanten
dc.subjectceftriaxoneen
dc.subjectoxacillinen
dc.subjectamoxicillinen
dc.subjectclavulanic aciden
dc.subjectBrazilen
dc.titleAntibiotic treatment schemes for very severe community-acquired pneumonia in children: a randomized clinical studyen
dc.typeArtigo
dcterms.licensehttp://www.scielosp.org/revistas/rpsp/iaboutj.htm
dcterms.rightsHolderPan Amer Health Organization
dspace.entity.typePublication
unesp.author.lattes9566480326705225
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Medicina, Botucatupt
unesp.departmentPediatria - FMBpt

Arquivos

Licença do pacote

Agora exibindo 1 - 2 de 2
Carregando...
Imagem de Miniatura
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Carregando...
Imagem de Miniatura
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição: